Corvus Pharmaceuticals Inc (NASDAQ:CRVS) saw its shares barely move in the early going Wednesday, having shared data from the Phase 3 mupadolimab COVID-19 trial.
The data from 40 patients suggested improvement in the primary and key secondary endpoints in patients treated with single doses of mupadolimab at 2mg/kg and 1mg/kg compared to placebo. The company adds no drug-related adverse events were reported.
The Company said antiviral responses in the 2mg/kg cohort trended higher across all variants tested, including delta.
In July, Corvus discontinued the COVID-19 trial, which had planned to enroll approximately 1,000 patients due to positive trends exhibited by COVID-19 vaccines.
In the 2mg/kg cohort, 93.3% of patients were alive and free from respiratory failure, compared to 85.7% in the 1mg/kg cohort and 81.1% in the placebo.
In addition, positive trends favoring mupadolimab treatment compared to placebo were seen for time to clinical improvement and hospital discharge.
Mupadolimab is currently being studied in a Phase 1b/2 study in patients with HPV+ oropharyngeal cancers and non-small cell lung cancers who have failed previous treatment with anti-PD-1 therapy and chemotherapy.
Said CEO Richard Miller, "We believe the results from our Phase 3 COVID trial show the potential for a dose response effect on the primary endpoint of time to respiratory failure or death for the 2mg/kg and 1mg/kg mupadolimab cohorts compared to placebo. Secondary endpoints also favored the cohorts receiving mupadolimab."
CRVS shares were down eight cents to $8.45 first thing Wednesday.
